Cross-linked hyaluronic acid dermal filler for deep wrinkles and facial volumising
Certifications
CE Marked hyaluronic acid dermal filler classified as a medical device within the EU/UK framework.
Manufactured in the Republic of Korea under medical device quality systems and imported into the EU/UK by authorised distributors.
Part of the Kairax HA filler professional system (Fine, Deep, Sub Q) promoted as fully CE approved with lidocaine Containing formulations.
CE Marked hyaluronic acid dermal filler classified as a medical device within the EU/UK framework.
Manufactured in the Republic of Korea under medical device quality systems and imported into the EU/UK by authorised distributors.
Part of the Kairax HA filler professional system (Fine, Deep, Sub Q) promoted as fully CE approved with lidocaine Containing formulations.
Supported by clinical and histological data for nasolabial fold correction and facial volumising as presented in Kairax marketing and brochure materials.
Cross-linked hyaluronic acid dermal filler for deep wrinkles and facial volumising
Description
Kairax™ Deep (1x1ml) is an advanced CE-marked hyaluronic acid dermal filler with lidocaine, engineered for deep wrinkle correction and facial volumising. Formulated with highly cross-linked, monophasic hyaluronic acid and 0.3% lidocaine in a 1 ml prefilled syringe, it offers high viscoelasticity for strong structural support while maintaining smooth, natural movement and expression. Kairax Deep is positioned as the medium-viscosity product within the Kairax range (Fine, Deep, Sub-Q) and is designed for mid-to-deep dermal injections. It effectively treats moderate to deep facial wrinkles and folds, and is widely used in lips, glabella lines, nasolabial folds, marionette lines, and nose and forehead contouring. The hydrophilic HA gel attracts and retains moisture, improving skin hydration and elasticity, while advanced cross-linking and mechanical processing provide long-lasting results with minimal swelling, less bruising and predictable, natural-looking enhancements.
Bnefits
CE-marked hyaluronic acid dermal filler with integrated 0.3% lidocaine for enhanced patient comfort during treatment.
Medium viscoelasticity gel optimised for mid-to-deep dermal augmentation and deep wrinkle correction.
Effective in treating moderate to deep wrinkles and folds such as nasolabial folds, marionette lines and deep-set lower-face wrinkles.
Versatile indication profile including lips, glabella lines, nasolabial folds, marionette lines, nose and forehead contouring, and cheek volumising.
High viscoelasticity and robust gel structure provide reliable structural support and contour definition.
Monophasic, highly purified cross-linked HA gel designed to integrate smoothly into tissues for natural-looking results.
Non-animal derived, biocompatible and biodegradable hyaluronic acid reduces risk of immunogenic reactions.
Formulation and cross-linking designed to minimise swelling and bruising, improving patient comfort and downtime.
Long-lasting performance, with typical results around 9–12 months depending on treatment area, technique and patient factors.
Stable gel with minimal migration after placement, helping to maintain shape and definition over time.
Supported by clinical and histological data for nasolabial fold correction and facial volumising as presented in Kairax marketing and brochure materials.
Correction of moderate to deep facial wrinkles and folds.
Treatment of nasolabial folds (nose-to-mouth lines).
Treatment of marionette lines (mouth-to-chin lines).
Deep wrinkle correction in the lower face.
Lip augmentation and contouring (volume and definition).
Glabella line softening (where appropriate and in line with injector training and local guidance).
Nose and forehead contouring in non-surgical rhinoplasty and profile balancing procedures.
Enhancement of midface and cheek volume and restoration of age-related volume loss.
General facial contouring and harmonisation requiring mid-to-deep dermal volume support.
Composition
Cross-linked hyaluronic acid 24 mg/ml (high-purity, non-animal origin; some distributors list 20 mg/ml for the Kairax range).
Lidocaine hydrochloride 0.3% (local anaesthetic to reduce injection pain).
BDDE (1,4-butanediol diglycidyl ether) as cross-linking agent – residual BDDE reported as not detected in some distributor specifications.
Physiological buffer solution (pH approximately 6.8–7.4) and excipients appropriate for injectable HA fillers.
Formulation
Monophasic, highly cross-linked hyaluronic acid gel with lidocaine, designed for deep wrinkle correction and volumising.
Medium gel viscosity (mid-range viscoelasticity) suitable for mid-to-deep dermal injection and structural support.
Hydrophilic HA matrix capable of binding up to 1000 times its weight in water, providing hydration and volume.
Sterile, pyrogen-free, isotonic, non-animal derived HA, produced under pharmaceutical-grade manufacturing standards.
Single-use, prefilled syringe system allowing smooth, controlled injection through supplied 27G needles.
Packaging
Box containing 1 x 1 ml prefilled glass syringe of Kairax™ Deep with lidocaine.
Includes 2 x sterile 27G needles for injection (Luer-lock).
Each box is labelled with product name, brand, lot/batch number, expiry date, and CE mark.
Supplied with instructions for use (IFU) detailing indications, injection depth, precautions and storage information.
Traceability labels for patient records and clinic documentation.
Usage
For use only by appropriately trained and qualified healthcare professionals with experience in dermal fillers and detailed knowledge of facial anatomy.
Inspect packaging and syringe before use; do not use if damaged, previously opened or past expiry date.
Disinfect the treatment area thoroughly and maintain strict aseptic technique throughout the procedure.
Attach the supplied 27G needle using the Luer-lock system and prime the syringe by expelling a small droplet of gel before injection.
Recommended injection depth for Kairax Deep is mid-to-deep dermis depending on the indication and anatomical area.
Inject slowly with gentle pressure; consider aspiration where appropriate to reduce risk of intravascular injection.
Use small aliquots and appropriate techniques such as linear threading, fanning or depot injections tailored to the treatment area (e.g. linear threading for nasolabial folds, small boluses for contouring).
Avoid injecting into blood vessels or areas with active skin disease, infection or inflammation.
After injection, gentle moulding or massage may be performed if necessary to achieve even distribution and desired contour, avoiding excessive pressure.
Advise patients to avoid touching or massaging the treated area, intense heat/cold, vigorous exercise and alcohol immediately after treatment, in line with clinic protocol.
Refer to the official Kairax brochure/IFU for full instructions, contraindications, and safety information, and adhere to local clinical guidelines and insurance requirements.
Contraindications
Hypersensitivity or known allergy to hyaluronic acid, lidocaine, amide-type local anaesthetics, or any of the components of the product.
History of severe allergic reactions or anaphylaxis unless a careful risk–benefit assessment has been made.
Presence of active skin infection or inflammation at or near the intended injection site (e.g. herpes, acne, dermatitis, cellulitis).
Autoimmune diseases or immunosuppression without specialist evaluation and explicit approval, given theoretical increased risk of inflammatory reactions.
Bleeding disorders or current use of anticoagulant or antiplatelet medications that significantly increase bleeding risk, unless managed appropriately.
Pregnancy or breastfeeding, as safety has not been established in these populations.
Patients under 18 years of age.
Injection into blood vessels, intramuscularly, or into areas with permanent fillers or foreign bodies without careful assessment.
Known porphyria or significant cardiac conduction disorders where lidocaine use may pose additional risk.
Any contraindications listed in the official Kairax instructions for use.
Adverse Effects
Common transient injection-site reactions including redness (erythema), swelling (oedema), tenderness or pain, bruising, itching, warmth or sensitivity, typically resolving within a few days to a week.
Local haematoma or bruising at injection sites.
Temporary lumps, nodules, induration or firmness at or near the injection area, usually improving with time and/or gentle massage if advised.
Asymmetry, overcorrection or undercorrection potentially requiring adjustment at follow-up.
Rare delayed inflammatory reactions or granuloma formation, as with other HA fillers, which may require medical management.
Infection at the injection site if aseptic technique is not strictly followed or if product is injected into infected tissue.
Very rare but serious complications from inadvertent intravascular injection, including vascular occlusion, tissue ischaemia, necrosis and, in high-risk areas, visual disturbance or blindness.
Systemic effects related to lidocaine in susceptible individuals or if maximum safe doses are exceeded, including CNS or cardiovascular symptoms; though unlikely at typical aesthetic doses, awareness is necessary.
Storage Conditions
Store at 2–25°C in a dry place.
Do not freeze.
Keep in the original blister and outer carton to protect from light and physical damage until use.
Do not use after the expiry date printed on the packaging.
Single-use sterile medical device: do not resterilise and do not reuse any remaining product, syringe or needle.
Dispose of used needles and syringes in approved sharps containers in accordance with local regulations.
Duration
Clinical and distributor information typically reports results lasting around 9\u201312 months, varying with treatment area, injected volume, technique and individual patient metabolism. Some patients may experience longer or shorter duration of effect.
Onset
Immediate visible improvement in volume and wrinkle correction is seen directly after injection, with final results refined over several days as transient swelling or redness subsides.
